Admetsys has been awarded Top Company by Tech Tour and the European Venture Contest at the 2015 Digital Health Venture Forum and has been nominated to present its Smart Pancreas™ technology for hospitalized diabetics at the 2015 European Venture Summit in Düsseldorf, Germany.
Boston-based Admetsys was the winner of The Venture Forum's ninth annual Five-Minute-Pitch contest, held in Worcester Tuesday. Admetsys CEO Jeff Valk gave the winning presentation, earning the $2,500 first prize and the $1,000 audience choice award.
At the Hatch pitch competition five companies came away victorious including Admetsys. The winners received first round interview at Entrepreneurs Roundtable Accelerator; slots in two other accelerators; credits for services from Microsoft and Amazon; entrepreneur office hours.
The Biobridge is an implant that has been shown to be able to guide the growth of new lymph channels. This technology can be used as an adjunct to existing treatments for the condition to hopefully improve outcomes. Fibralign has benefited from grants from the DoD and NSF to support a large animal study and develop production tools for making its initial product.
Fibralign's first product, BioBridge, is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120 million people and has no cure. The company successfully completed a large animal study that validated BioBridge-treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study.